125 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
7 May 24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
4:02pm
will split global development costs for seralutinib, except for the PROSERA Study, for which Gossamer will remain solely responsible. Gossamer remains … will be solely responsible for commercialization of seralutinib outside of the United States, for which Gossamer will receive mid-to-high teens royalties
8-K
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
of the PROSERA Phase 3 study, which Gossamer will be solely responsible for conducting at Gossamer’s own cost and expense. With respect to each country
8-K
EX-99.1
csig6 a8usm1x
6 May 24
Entry into a Material Definitive Agreement
7:31am
8-K
EX-3.1
m5b19sirf 75fmdu
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
aoeapzr8lqias c4qaz
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
424B3
a320r3l bz9
28 Aug 23
Prospectus supplement
4:29pm
UPLOAD
1j6b23k5 vk8ew2q8rq
24 Aug 23
Letter from SEC
12:00am
S-3
ny5tk
18 Aug 23
Shelf registration
8:41am
S-3ASR
vbxh14ud1g
17 Aug 23
Automatic shelf registration
4:01pm